Cell line · CVCL_0320
Papers395
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 395
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Mucin-rich environment shapes Pseudomonas aeruginosa cytotoxicity and phage-mediated epithelial protection. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Photodynamic and Cytotoxic Evaluation of Euphorbia anacampseros Methanolic Extract: Chemical Characterization, Molecular Docking, and Light-Activated Anticancer Activity. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PSY Inhibits Colorectal Cancer Growth and Exhibits an In Vitro Synergistic Interaction with 5-Fluorouracil. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Psychological Stress Disrupts Goblet Cell Function and Intestinal Barrier via 5-HT/HTR7-Mediated NLRP6 and Autophagy Suppression. | Biology (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-content morphological profiling by Cell Painting in 3D spheroids. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Biological Evaluation of Benzimidazolium-Chalcone Derivatives: Antioxidant, Anti-AChE, Anticancer, and Anti-MRSA Activities With Docking Insights. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor-Relevant Evaluation of Liquid and Microencapsulated Lepidium meyenii and Bactris gasipaes Extracts Reveals Species- and Formulation-Dependent Activity. | Molecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Impact of Combretastatin A-4 on Cancer Cells and Circulating Tumor Cells (CTCs): A Multi-Assay Approach. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Endogenous CRISPR-Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe-by-Design Approach. | Microb Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Slap restricts oncogenic Src-family kinase signaling to maintain colonic epithelial homeostasis. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer. | Int J Med Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The long non-coding RNA-encoded microprotein MKKS3 drives colorectal cancer chemoresistance. | Exp Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| P2Y2 Receptor Controls TLR3-Induced Chemokine Production in Intestinal Epithelial Cells. | J Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Metabolic Targeting of Cancer: Lessons from Metformin and 2-Deoxy-D-Glucose Combinations. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fibroblasts selectively modulate immune cell-derived cytokine effects on tumor cells in colorectal cancer. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancer. | Cancer Drug Resist | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0320/papers